The RIO study is looking at whether a new bNAb treatment can keep viral load undetectable without antiretroviral treatment (ART) and involved asking all participants to stop ART for a short time. 

The study aimed to measure how long viral load stays undetectable without ART, as well as look at what happens to the HIV virus and immune system in blood samples. When virus becomes detectable in a blood test (viral rebound) the participants were then asked to re-start their ART.

This publication discusses the secondary outcomes of the Rio trial. it looks at viral rebound antibody sensitivity and reservoir dynamics. The publication also looks at the exploratory outcomes of the trial which looked at rebound virus evolution and autologous antibody activity.

Read the publication here:

Broadly neutralizing antibodies in adult males living with HIV undergoing analytical treatment interruption: secondary and exploratory outcomes of the phase II randomized controlled RIO trial